Vascular endothelial growth factor concentrations in aqueous humor before and after subconjunctival injection of bevacizumab for neovascular glaucoma.
Mizote
Masanori
M
Baba
Tetsuya
T
Hirooka
Kazuyuki
K
Yamaji
Hidetaka
H
Shiraga
Fumio
F
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001082:Aqueous Humor / Q000378:metabolism*; D000068258:Bevacizumab; D003228:Conjunctiva; D005260:Female; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D014130:Trabeculectomy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab